Comparative Pharmacology
Head-to-head clinical analysis: FLUOXYMESTERONE versus KYZATREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXYMESTERONE versus KYZATREX.
FLUOXYMESTERONE vs KYZATREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Kyzatrex is a synthetic analog of human growth hormone (hGH). It binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway, which stimulates insulin-like growth factor 1 (IGF-1) production in the liver and other tissues, promoting growth and anabolic effects.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
400 mg orally once daily, with or without food.
None Documented
None Documented
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Terminal elimination half-life is 18 hours (range 14-22 h) in adults with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life prolongs to 28 hours; in severe impairment (CrCl <30 mL/min), half-life exceeds 40 hours, necessitating dose adjustment.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Primarily renal excretion (85% unchanged, with active tubular secretion). Biliary/fecal elimination accounts for 10%, and 5% is metabolized via hepatic CYP3A4 before renal elimination.
Category C
Category C
Androgen
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."